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Despite major advances in HIV-1 therapeutics and prevention strategies, the development of a safe
and effective prophylactic HIV-1 vaccine will likely be critical for ending the global HIV-1 epidemic.
Yet only four HIV-1 vaccine concepts have been tested for clinical efficacy over the past 30 years. In
this Commentary, we describe key hurdles facing the HIV-1 vaccine development field and outline
strategies to accelerate efficacy evaluation of novel HIV-1 vaccine candidates.Current State of the HIV-1 Vaccine
Field
Despite the urgent need for a globally
effective prophylactic HIV-1 vaccine,
only four HIV-1 vaccine concepts have
been tested in six clinical efficacy trials
to date (Table 1). These concepts have
included (1) Env gp120 proteins, (2) re-
combinant adenovirus serotype 5 (rAd5)
vectors, (3) canarypox (ALVAC) vectors
with gp120 boosts, and (4) DNA vaccines
with a rAd5 boost. The first efficacy
studies evaluated monomeric HIV-1 en-
velope (Env) gp120 protein vaccines
with alum adjuvant and were tested in
two phase III vaccine trials. These vac-
cines failed to prevent HIV-1 acquisition
in men who have sex with men (MSM)
and high-risk women in the United States
and Europe (Vax004) (Flynn et al., 2005),
as well as in injection drug users in
Thailand (Vax003) (Pitisuttithum et al.,
2006).
A rAd5 vector-based vaccine express-
ing the HIV-1 internal proteins gag/pol/
nef was then tested in the Step (HVTN
502) and Phambili (HVTN 503) phase IIb
trials. The Step trial, which was conduct-
ed in MSM and high-risk women in the
Americas, Caribbean, and Australia, was
stopped for futility to block HIV-1 acquisi-
tion (Buchbinder et al., 2008). Subsequent
analyses suggested an increase in HIV-1
acquisition in vaccinees, particularly in
the subgroup of uncircumcised men who
were seropositive at baseline for Ad5.
This finding cast a pall over the HIV-1
vaccine development field and led to
increased research emphasis on the
potential importance of vector-specific
immune responses. The Phambili studytested the same vaccine in high-risk
heterosexuals in South Africa and was
stopped during its enrollment phase
shortly after the Step results were
announced (Gray et al., 2011). Unblinded
follow-up of Phambili participants sug-
gested a very late effect of excess HIV-1
infections in heterosexual male vaccinees
without a clear mechanism of action (Gray
et al., 2014). Concordant with the lack of
efficacy observed in these clinical trials,
preclinical studies similarly demonstrated
that analogous rAd5 vectors expressing
gag/pol/nef from the related simian
immunodeficiency virus (SIV) afforded
no protection against acquisition of infec-
tion following mucosal SIV challenges in
rhesus monkeys (Reynolds et al., 2012).
The third vaccine concept involved
priming with a canarypox vector (ALVAC)
expressing the HIV-1 antigens gag/pol/
env and boosting with the same gp120
protein subunits that were used in the
Vax003 study. The RV144 study was
conducted in a low-incidence, mostly
heterosexual population in Thailand and
demonstrated vaccine efficacy of 31%
at 42 months (Rerks-Ngarm et al., 2009).
Efficacy was 60% at 12 months, indica-
tive of an early protective effect that
waned over time. Subsequent analyses
demonstrated that the risk of HIV-1 infec-
tion correlated inversely with antibodies
directed against the first and second
HIV-1 Env variable regions (V1V2) and
correlated directly with Env-specific IgA
antibodies (Haynes et al., 2012). Addi-
tional analyses suggested that HIV-1
infection risk also inversely correlated
most clearly with V2-specific antibodies
of the IgG3 isotype and non-neutralizingCell 159, Nfunctional activity. Furthermore, a mole-
cular sieve analysis showed immune
selection pressure on specific V2 amino
acids in vaccinees (Rolland et al., 2012).
Consistent with the clinical results,
modest protective efficacy was also
observed with analogous ALVAC/gp120
vaccines against mucosal SIV challenges
in rhesus monkeys.
The fourth vaccine concept that was
tested involved priming with DNA vac-
cines expressing gag/pol/nef/env and
boosting with rAd5 vectors expressing
gag/pol/env in the HVTN 505 study, which
was a phase IIb study conducted in MSM
in the Americas. Importantly, preclinical
data showed that this vaccine afforded
partial protection against low-stringency
SIV challenges (strain SIVsmE660) in
rhesus monkeys but failed to protect
against high-stringency SIV challenges
(strain SIVmac251) (Letvin et al., 2011).
HVTN 505 was halted at its first interim
efficacy analysis for futility to protect
against HIV-1 acquisition or lower HIV-1
viral RNA in breakthrough infections
(Hammer et al., 2013). These data
strongly suggest that preclinical studies
of HIV-1 vaccines should be evaluated
exclusively in stringent preclinical chal-
lenge models.
Future HIV-1 Vaccine Efficacy
Studies
Several HIV-1 vaccine candidates are
expected to be evaluated in clinical effi-
cacy studies in the next few years. The
Poxvirus-Protein Public Private Partner-
ship (‘‘P5’’) is a collaborative group that
has been formed to build on the results
of the RV144 trial and to test the identifiedovember 20, 2014 ª2014 Elsevier Inc. 969
Table 1. Clinical HIV-1 Vaccine Efficacy Trials
Study Vaccines Phase Risk Group
HIV Incidence per
100 Person-Years Location Result
Vax003 AIDSVAX B/E
gp120 in alum
III injecting drug users 3.40% Thailand no vaccine efficacy
Vax004 AIDSVAX B/B
gp120 in alum
III high-risk women
and MSM
2.60% United States,
Europe
no vaccine efficacy
HVTN 502 MRKAd5 HIV-1
gag/pol/nef B
IIb high-risk women
and MSM
3.00% United States halted at interim analysis
for futility; early transient
increased infection
in vaccinees
Step
HVTN 503 MRKAd5 HIV-1
gag/pol/nef B
IIb high-risk heterosexual
men and women
3.70% South Africa no vaccine efficacy;
late increased HIV infection
in unblinded male vaccinees
Phambili
RV144 ALVAC-HIV vCP1521,
AIDSVAX B/E
rgp120 in alum
III community risk
heterosexual men
and women
0.28% Thailand 31.2% efficacy at 42 months
as primary endpoint;
60% efficacy at 12 months
HVTN 505 DNA, rAd5 (A, B, C) IIb circumcised MSM
without pre-existing
Ad5 antibodies
1.80% United States halted at interim
analysis for futility
MSM, men who have sex with men; Ad5, adenovirus serotype 5.V2 correlate of risk in a new series of HIV-
1 vaccine efficacy trials in sub-Saharan
Africa and Thailand. For studies in Africa,
new ALVAC and gp120 vaccine products
with HIV-1 clade C antigens are currently
being manufactured. ALVAC vectors
expressing clade C antigens and MF59-
adjuvanted gp120 subunits are planned
for a phase III licensure study in sub-
Saharan Africa. Other strategies, includ-
ing NYVAC and DNA-NYVAC priming
prior to gp120 boosting, are planned
for evaluation in non-licensure track
phase IIb efficacy studies. High-risk
MSM cohorts are also being explored in
Thailand for further efficacy testing.
Additional HIV-1 vaccine candidates
are also being developed for efficacy
testing. A recombinant adenovirus sero-
type 26 (rAd26) prime expressing gag/
pol/env with a modified vaccinia Ankara
(MVA) boost expressing the same anti-
gens has shown substantial protection
against both SIVmac251 and SHIV-
SF162P3 challenges in rhesus monkeys
(Barouch et al., 2012, 2013). Boosting
with an Env gp140 trimer appears to
improve this observed protective efficacy
in monkeys (D.H.B., unpublished data).
A prototype rAd26 vector expressing env
was also recently shown to be safe and
immunogenic in humans with no evidence
for activation of total or vector-specific
CD4+ T cells in colorectal mucosa (Baden970 Cell 159, November 20, 2014 ª2014 Elseet al., 2014). A multivalent Ad26/MVA
vaccine expressing HIV-1 ‘‘mosaic’’ gag/
pol/env immunogens designed for
optimal coverage of global virus diversity,
together with a stable Env gp140 trimer,
are expected to enter clinical trials later
this year. These Ad26/MVA and Ad26/
gp140 vaccines are currently under con-
sideration for advancement into efficacy
testing.
Other promising vaccine candidates
that have entered early phase clinical tri-
als include priming with DNA vaccines
and boosting with MVA vectors. In addi-
tion, early phase clinical trials are planned
with cytomegalovirus (CMV) vectors,
which showed substantial virologic con-
trol and possible clearance of SIVmac251
in approximately half of vaccinated
monkeys following challenge (Hansen
et al., 2013).
Why So Few HIV-1 Vaccine Efficacy
Studies?
Why have so few HIV-1 vaccine efficacy
trials been conducted to date for a
problem of such global importance?
Factors include the enormous scientific
challenges in designing a vaccine for a
highly variable virus that integrates in the
host genome, rapidly establishes latency,
and effectively evades both humoral
and cellular immune responses. Although
certain correlates of risk were identifiedvier Inc.in the RV144 study, it is currently not clear
whether these are true mechanistic corre-
lates of protection or whether they will
prove generalizable beyond the RV144
study. In addition, although nonhuman
primate challenge models have proven
informative, they do not yet represent
validated animal models that are neces-
sarily predictive of clinical efficacy trials.
As a result, large, complex, iterative
clinical efficacy studies are required to
show the efficacy of candidate HIV-1 vac-
cines in humans. Moreover, the primary
endpoint of such studies has to be inci-
dent new HIV-1 infections in large popula-
tions of high risk individuals. Such studies
are expensive and logistically challenging,
and thus they pose substantial risk to the
pharmaceutical industry that traditionally
drives advanced clinical development of
vaccines.
Accelerating Clinical Efficacy Trials
Accelerating efficacy testing of novel and
promising HIV-1 vaccine candidates will
be vital for the field. In the absence of
a validated and generalizable immune
correlate of protection, only carefully
designed clinical efficacy trials can deter-
mine whether a HIV-1 vaccine works in
humans. The results of such trials, regard-
less of their outcomes, will have major
impacts on the HIV-1 vaccine field, and
they will lead to immediate prioritization
and deprioritization of vaccine candidates
and strategies. Studies that show partial
protective efficacy will also refine our
understanding of immune correlates of
protection. The efficacy trials conducted
to date have had surprising outcomes
that have been discordant with the ex-
pectations of experts in the field, and
thus the current state of knowledge
is inadequate to predict the results of
any such efficacy trials with certainty.
To accelerate efficacy testing of next-
generation HIV-1 vaccine candidates,
increased industry involvement, mobiliza-
tion of resources, expansion of the current
vaccine pipeline, and robust preclinical
challenge studies will likely prove critical.
Increased industry involvement would
be highly desirable for the HIV-1 vaccine
field, particularly for advanced clinical
development. Industry provides unique
expertise in terms of manufacturing, regu-
latory affairs, and product development,
as well as downstream licensure capacity
to produce and to deliver a vaccine in
the event that efficacy trials are success-
ful. Currently, industry involvement has
been relatively modest for the reasons
described previously. Both the NIH and
the Bill & Melinda Gates Foundation
have programs that actively support aca-
demic-industry partnerships, and these
programs should be continued and ex-
panded. Engaging and encouraging in-
dustry involvement at the earliest stages
in vaccine development may interest a
potential industry partner in a particular
vaccine platform and may lead to in-
creased involvement for advanced clinical
development should the scientific ratio-
nale prove compelling. Early involvement
of industry may also be critical, as com-
panies may need the use of particular
raw materials, cell lines, vectors, or
manufacturing technologies to be con-
sistent with their internal platforms or
processes.
The size, cost, and logistic complexity
of HIV-1 vaccine efficacy trials are sub-
stantial. Thus, in addition to the major
current investments from the NIH, Gates
Foundation, and multiple other organi-
zations, mobilization of new resources
would greatly accelerate HIV-1 vaccine
efficacy studies. Three potential sources
for new funding include industry, govern-
ments, and additional philanthropy. Phar-
maceutical companies may provide directsupport for development activities,
including clinical efficacy trials, if they
are sufficiently interested in a particular
vaccine product. Additional investment
of governments worldwide would be
highly enabling for the field. Finally, new
philanthropic funding will also accelerate
the development of an HIV-1 vaccine,
as exemplified by the Ragon Institute of
MGH, MIT, and Harvard.
Accelerating clinical efficacy trials of
HIV-1 vaccine candidates also requires
multiple distinct and scientifically prom-
ising vaccine candidates in preclinical
and early phase clinical studies to be
ready for efficacy testing. It is therefore
essential to maintain and expand a
diverse portfolio of vaccine concepts.
For example, novel Env immunogens are
being developed by multiple groups to
elicit broadly neutralizing antibodies as
well as to optimize functional non-neutral-
izing antibodies; a series of new vectors
have been explored that expand the
breadth and efficacy of virus-specific
T cell responses; and potential global
antigens have been developed that
begin to address the challenge of global
virus diversity. A robust pipeline of
new concepts and fresh perspectives
will also require the engagement and
encouragement of young and early career
investigators, particularly those from the
developing world.
Expanding preclinical efficacy studies
will also help to support the rationale for
clinical efficacy trials. Although the ability
of nonhuman primate challenge studies
to predict the outcomes of clinical effi-
cacy trials still remains uncertain, strin-
gent SIV and SHIV challenges in rhesus
monkeys represent the most robust
model for assessing vaccine candidates
prior to clinical efficacy trials. Such
preclinical challenge studies should
therefore be expanded, particularly for
vaccine candidates under consideration
for efficacy trials. When clinical efficacy
data with these vaccines become avail-
able, the clinical results can then be
used to refine and to improve the preclin-
ical models.
Perspectives
HIV-1 vaccine development will likely be
an iterative process. Robust basic
research must continue but needs to be
matched with clinical efficacy testing ofCell 159, Npromising new vaccine candidates. Infor-
mation learned from each rigorous effi-
cacy trial will be pivotal and will provide
clear directions for the field. A more
detailed understanding of immune corre-
lates of protection will also be obtained
from these clinical efficacy trials and
may, ultimately, reduce the need to
conduct large studies for each new
vaccine concept. However, at the present
time, there is no way to determine
whether a vaccine will prevent HIV-1
infection in humans other than clinical
efficacy studies in which incident new
HIV-1 infections are the primary endpoint.
There are numerous reasons for
optimism in the HIV-1 vaccine field.
The RV144 study showed that an HIV-1
vaccine is possible, and several novel
vaccine candidates have demonstrated
unprecedented efficacy in stringent
nonhuman primate challenge studies.
Our basic understanding of HIV-1-spe-
cific humoral and cellular immunity has
expanded considerably, and preclinical
and clinical immune correlates of pro-
tection have been identified in certain
contexts. Increasing the momentum to
accelerate the conduct of efficacy trials
will substantially accelerate the develop-
ment of a safe and effective HIV-1 vac-
cine, which will presumably be required
to control the global HIV-1 pandemic.ACKNOWLEDGMENTS
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